¼¼°èÀÇ ¿©¼º ¼º±â´É Àå¾Ö Ä¡·á ½ÃÀå
Female Sexual Dysfunction Treatment
»óǰÄÚµå : 1774834
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 478 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ¿©¼º ¼º±â´É Àå¾Ö Ä¡·á ½ÃÀåÀº 2030³â±îÁö 8¾ï 5,380¸¸ ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 5¾ï 2,860¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¿©¼º ¼º±â´É Àå¾Ö Ä¡·á ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 8¾ï 5,380¸¸ ´Þ·¯¿¡ À̸£°í, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 8.3%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Female Sexual Dysfunction Treatment,¿©¼º¼º±â´ÉÀå¾Ö,¿©¼º¼º±â´ÉÀå¾ÖÄ¡·áÀº CAGR 8.6%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 3¾ï 4,240¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Bremelanotide ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 5.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 4,400¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 13.0%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ ¿©¼º ¼º±â´É Àå¾Ö Ä¡·á ½ÃÀåÀº 2024³â¿¡ 1¾ï 4,400¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â°£ CAGR 13.0%·Î 2030³â±îÁö 1¾ï 8,460¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 4.2%¿Í 8.0%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.5%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ¿©¼º ¼º±â´É Àå¾Ö Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¿©¼º ¼º±â´É Àå¾Ö°¡ ¸¶Ä§³» ÀÓ»óÀû, »ó¾÷ÀûÀ¸·Î ÁÖ¸ñ¹Þ°Ô µÈ ÀÌÀ¯´Â ¹«¾ùÀϱî?

¼ö½Ê³âµ¿¾È Á¦ÇÑÀûÀ¸·Î ÀÎ½ÄµÇ¾î ¿Ô´ø ¿©¼º ¼º±â´É Àå¾Ö(FSD)´Â ÀÌÁ¦ ½É°¢ÇÑ ´Ù¸éÀû °Ç°­ ¹®Á¦·Î ÀνĵǾî ÀÓ»óÀû °ü½É°ú ½ÃÀå °³Ã´¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖÀ¸¸ç, ¼º¿å °¨Åð(¼º¿å °¨Åð), ÈïºÐ Àå¾Ö, ¿À¸£°¡Áò ±â´É Àå¾Ö, ¼º±³Åë°ú °°Àº ÅëÁõ°ú °ü·ÃµÈ ´Ù¾çÇÑ Áõ»óÀ» Æ÷ÇÔÇÕ´Ï´Ù. µî ´Ù¾çÇÑ Áõ»óÀ» Æ÷ÇÔÇÕ´Ï´Ù. ¿ª»çÀûÀ¸·Î »çȸÀû ±Ý±â, Æí°ß, ÀÇÇÐÀû ÈÆ·ÃÀÇ ºÎÁ·À¸·Î ÀÎÇØ °ú¼Ò Áø´ÜµÇ¾î ¿Ô´ø ÀÌ ÁúȯÀº ¿©¼ºÀÇ Àü¹ÝÀûÀÎ °Ç°­°ú ÇູÀ» ±¸¼ºÇÏ´Â Á¤´çÇÑ ¿ä¼Ò·Î °£Áֵǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â ¹®È­Àû ŵµÀÇ º¯È­, °Ç°­ ¿ËÈ£¿¡¼­ ¿©¼ºÀÇ ¸ñ¼Ò¸®°¡ Ä¿Áö°í, »ý½Ä °Ç°­À» ³Ñ¾î¼± ¼º °Ç°­ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¿ä±¸°¡ ³ô¾ÆÁø µ¥ ±âÀÎÇÕ´Ï´Ù. ÀÌ¿¡ µû¶ó ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü¿Í Á¦¾àȸ»ç´Â ³²¼ºÀÇ ¼º±â´É Àå¾Ö¿¡ Àû¿ëµÇ´Â °Í°ú µ¿ÀÏÇÑ °úÇÐÀû ¾ö°ÝÇÔÀ¸·Î FSD¿¡ Á¢±ÙÇϱ⠽ÃÀÛÇß½À´Ï´Ù. ¿©±â¿¡´Â ±¸Ã¼ÀûÀÎ Áø´Ü ±âÁØÀÇ °³¹ß, Çø®¹Ý¼¼¸°À̳ª ºê·¹¸á¶ó³ëŸÀ̵å¿Í °°Àº FDA ½ÂÀÎ Ä¡·á¹ý, FSDÀÇ ±Ù°£ÀÌ µÇ´Â È£¸£¸ó, ½Å°æ, ½É¸®, °ü°è ¿äÀÎÀ» ÀÌÇØÇϱâ À§ÇÑ ÀÓ»ó ¿¬±¸ÀÇ ¹ßÀüÀÌ Æ÷ÇԵ˴ϴÙ.

ÀǾàǰ°ú ºñÀǾàǰÀÇ Çõ½ÅÀº Ä¡·áÀÇ Àü¸ÁÀ» ¾î¶»°Ô ¹Ù²Ù°í Àִ°¡?

FSD Ä¡·áÀÇ Àü¸ÁÀº È£¸£¸ó ¿ä¹ý¿¡ ±¹ÇѵÇÁö ¾Ê°í, ÀǾàǰ°ú ºñÀǾàǰÀ» ÅëÇÑ ´Ù¾çÇÑ Ä¡·á ¿É¼ÇÀ¸·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¿¡½ºÆ®·Î°Õ º¸ÃæÀ̳ª ¾Èµå·Î°Õ ¿ä¹ý°ú °°Àº ÀüÅëÀûÀÎ Ä¡·á¹ýÀº ÇöÀç ¼¼·ÎÅä´Ñ°ú µµÆÄ¹Î °æ·Î¸¦ Ç¥ÀûÀ¸·Î ÇÏ¿© ¼º¿åÀ» °­È­ÇÏ´Â Çø®¹Ý¼¼¸°°ú °°Àº ÁßÃ߽Űæ°è ¾à¹°¿¡ ÀÇÇØ º¸¿ÏµÇ°í ÀÖ½À´Ï´Ù. ¸á¶ó³ëÄÚ¸£Æ¾ ¼ö¿ëü ÀÛ¿ëÁ¦ÀÎ ºê·¹¸á¶ó³ëŸÀ̵å´Â Æó°æ Àü ¿©¼º¿¡°Ô ¿Âµð¸Çµå ¿ä¹ýÀ» Á¦°øÇÏ´Â ¶Ç ´Ù¸¥ ȹ±âÀûÀÎ ¾à¹°ÀÔ´Ï´Ù. ÀÌ¿Í º´ÇàÇÏ¿© ¿¬±¸ÀÚµéÀº ¿Á½ÃÅä½Å À¯»çü ¹× ¼±ÅÃÀû ¿¡½ºÆ®·Î°Õ ¼ö¿ëü Á¶ÀýÁ¦¸¦ Æ÷ÇÔÇÑ »õ·Î¿î ¾à¹° °è¿­À» Ž»öÇϰí ÀÖÀ¸¸ç, ÀϺΠ¾à¹°Àº ´Ù¾çÇÑ ÀÓ»ó½ÃÇè ´Ü°è¿¡ ÀÖ½À´Ï´Ù. ºñ¾à¸®ÇÐÀû Á¢±Ù¹ýµµ ƯÈ÷ ÀüÀÎÀû ¶Ç´Â ºñħ½ÀÀû ´ë¾ÈÀ» ¿øÇÏ´Â ¿©¼ºµé¿¡°Ô Å« ÁöÁö¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â ÀÎÁöÇൿġ·á, ¸¶À½Ã¬±è¿¡ ±â¹ÝÇÑ ÁßÀç, °ñ¹ÝÀú ¹°¸®Ä¡·á, Áú ·¹ÀÌÀú ¹× ½Å°æ Á¶Àý µµ±¸¿Í °°Àº ÷´Ü ÀåºñÀÇ »ç¿ë µîÀÌ Æ÷ÇԵ˴ϴÙ. ¿ø°Ý ÀÇ·á Ç÷§Æû°ú µðÁöÅÐ Ä¡·á¹ýÀº ƯÈ÷ ¼­ºñ½º¸¦ ÃæºÐÈ÷ ¹ÞÁö ¸øÇϰųª º¸¼öÀûÀΠȯ°æ¿¡ ÀÖ´Â ¿©¼ºµé¿¡°Ô º¸´Ù Ä£¼÷Çϰí, ½ÅÁßÇϸç, ¸ÂÃãÈ­µÈ Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù. ¼º °Ç°­ÀÌ ´õ ±¤¹üÀ§ÇÑ ¿©¼º °Ç°­ ¾Û¿¡ ÅëÇյǸé FSD´Â ´õ¿í ºñ´ëĪȭµÇ¾î Áõ»ó ÃßÀû, Çൿ ¼öÁ¤ ¹× °¡»ó »ó´ãÀÌ ¿ëÀÌÇØÁý´Ï´Ù.

¾î¶² ¹®È­Àû, ½É¸®Àû, Àα¸Åë°èÇÐÀû º¯È­°¡ Ä¡·áÀÇ º¸±ÞÀ» ÃËÁøÇϰí Àִ°¡?

¹®È­Àû À̾߱â, ½É¸®Àû ÀνÄ, Àα¸Åë°èÇÐÀû ÆÐÅÏÀÇ º¯È­°¡ FSD Ä¡·á¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¿©¼ºÀÇ ¼½½´¾ó¸®Æ¼¿¡ ´ëÇÑ »çȸÀû ¼ö¿ë°ú ±³À°ÀÌ È®»êµÇ¸é¼­ ¿À´Ã³¯ÀÇ ¿©¼ºµéÀº ÀÚ½ÅÀÇ ¼ºÀû ¾È³çÀ» ¿ì¼±½ÃÇϰí ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü¿Í °ø°³ÀûÀ¸·Î ¼ÒÅëÇÒ ¼ö ÀÖ´Â ÈûÀÌ ´õ °­ÇØÁ³½À´Ï´Ù. ƯÈ÷ ¹Ð·¹´Ï¾ó ¼¼´ë¿Í Z¼¼´ë´Â ¼º °Ç°­À» ±Ý±â½ÃÇÏ´Â °ÍÀÌ ¾Æ´Ï¶ó »îÀÇ Áú(QOL)ÀÇ ¹®Á¦·Î ÀçÁ¤ÀÇÇÏ´Â µ¥ ÀÏÁ¶Çϰí ÀÖÀ¸¸ç, ±×µ¿¾È °£°úµÇ¾î ¿Ô´ø Æó°æ±â ÀÌÈÄ ¿©¼ºµéÀº ³ëÈ­¿¡ µû¸¥ ¼º¿å°ú Æí¾ÈÇÔÀÇ º¯È­¿¡ ´ëóÇÒ ¼ö ÀÖ´Â ÇØ°áÃ¥À» ã°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¤½Å°Ç°­°ú ¼º±â´ÉÀÇ ¿¬°ü¼º¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ºÒ¾È, ½Åü À̹ÌÁö, °ü°èÀÇ ¿ªÇÐ µî ½É¸®Àû ¿äÀÎÀÌ Áø´Ü ¹× Ä¡·á °úÁ¤ÀÇ ÀϺΰ¡ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²², À£ºù ¹®È­, ¹Ùµð Æ÷ÁöƼºê, ¼½½º Æ÷ÁöƼºê, Æä¹Ì´ÏÁòÀÇ ÀαⰡ ³ô¾ÆÁö¸é¼­ ¼ºÀûÀÎ ¸¸Á·À» Áö¿øÇÏ´Â Á¦Ç° ¹× ¼­ºñ½º¿¡ ´ëÇÑ ¼ÒºñÀÚ Á᫐ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±× °á°ú, ¿©¼ºµéÀº Àü¹® Ŭ¸®´Ð, ¿Â¶óÀÎ Ç÷§Æû, ¼Ò¸Å À£´Ï½º ºê·£µå¿¡¼­ ÀÓ»ó Ä¡·á¿Í ¶óÀÌÇÁ½ºÅ¸ÀÏÀ» °³¼±ÇÏ´Â º¸ÃæÁ¦¸¦ ¸ðµÎ ã°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀνÄÀÇ º¯È­´Â º¸´Ù ¼ö¿ëÀûÀÎ ½ÃÀå ȯ°æÀ» Á¶¼ºÇϰí ȯÀÚ¿Í ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü »çÀÌ¿¡ º¸´Ù °ß°íÇÑ ³íÀǰ¡ ÀÌ·ç¾îÁöµµ·Ï À¯µµÇϰí ÀÖ½À´Ï´Ù.

¼¼°è ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­ÇÏ´Â ¾÷°è ¼¼·Â°ú ÀÓ»óÀû ¿ä±¸´Â ¹«¾ùÀΰ¡?

¿©¼º ¼º±â´É Àå¾Ö Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ÀÇÇÐÀÇ ¹ßÀü, ¼ÒºñÀÚ ¼±È£µµ º¯È­, ÀÇ·á ¼­ºñ½º Á¦°ø ½Ã½ºÅÛÀÇ ¹ßÀü¿¡ ±â¹ÝÇÑ ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °¡Àå Áß¿äÇÑ °ÍÀº ¿©¼º Áß½ÉÀÇ ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ ÀνÄ, ±³À° ¹× Á¢±Ù¼º Çâ»ó¿¡ ÈûÀÔ¾î ¼º °Ç°­À» À§ÇØ ÀÇ·á °³ÀÔÀ» ã´Â ¿©¼ºµéÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ±â¾÷ ÇÁ·ÎÆÄÀÏÀº ¿©·¯ FSD ¾ÆÇü ¹× È£¸£¸ó ÇÁ·ÎÆÄÀÏ¿¡ ´ëÇÑ ¾à¹° ÆÄÀÌÇÁ¶óÀÎÀ» ´Ã¸®¸é¼­ Ç¥Àû Ä¡·áÁ¦ÀÇ ¿¬±¸°³¹ß¿¡ Àû±ØÀûÀ¸·Î ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¿ø°Ý ÀÇ·á ¹× ¼ÒºñÀÚ Á÷Á¢ ÆÇ¸Å Ç÷§ÆûÀÇ È®´ë·Î ÀÎÇØ, ƯÈ÷ ¼º °Ç°­¿¡ ´ëÇÑ Á÷Á¢ÀûÀÎ ³íÀǰ¡ ±Ý±â½ÃµÇ´Â ½ÃÀå¿¡¼­ ºñ¹Ð »ó´ã ¹× ó¹æ ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Å©°Ô °³¼±µÇ°í ÀÖ½À´Ï´Ù. ¼±Áø±¹ÀÇ ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í º¸Çè Àû¿ë ¹üÀ§ÀÇ È®´ë·Î ÀÎÇØ ´õ ¸¹Àº ¿©¼ºµéÀÌ ÀüÅëÀûÀÎ Ä¡·á¹ý°ú »õ·Î¿î Ä¡·á¹ýÀ» ¸ðµÎ °í·ÁÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, Àü ¼¼°è ¿©¼º Àα¸ÀÇ °í·ÉÈ­(ƯÈ÷ Æò±Õ ¼ö¸íÀÌ ±ä Áö¿ª)´Â Æó°æ ÈÄ ¼º °Ç°­ ¼Ö·ç¼Ç¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. »êºÎÀΰú ÀÇ»ç, ³»ºÐºñ Àü¹®ÀÇ, Á¤½Å °Ç°­ Àü¹®°¡, ¼º °Ç°­ Àü¹®°¡µé °£ÀÇ ºÐ¾ß °£ Çù·Â °ü°è´Â FSDÀÇ º¹ÀâÇÑ Æ¯¼º¿¡ ´õ Àß ´ëóÇÒ ¼ö ÀÖ´Â ´ÙÇÐÁ¦Àû Ä¡·á ¸ðµ¨À» °­È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº ¿µ¾ç º¸ÃæÁ¦, À±È°À¯, ±â¼ú ±â¹Ý Ä¡·á ¼Ö·ç¼Ç µî ¼º °Ç°­¿¡ ´ëÇÑ À£´Ï½º ¾÷°èÀÇ ÅõÀÚ·Î ´õ¿í Ȱ¼ºÈ­µÇ°í ÀÖÀ¸¸ç, ÀÌ´Â FSD Ä¡·áÀÇ Àüü »ýŰ迡 ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

¾à¹°(Çø®¹Ý¼¼¸°, ºê·¹¸á¶ó³ëŸÀ̵å, ¿À½ºÆä¹ÌÆæ, ¿¡½ºÆ®·Î°Õ ¿ä¹ý, ±âŸ ¾à¹°); Áúº´(¼º±³Åë Áúȯ, ¼º¿åÀúÇÏ Àå¾Ö Áúȯ, ±âŸ Áúȯ); Åõ¿© °æ·Î(°æ±¸, ºñ°æ±¸, ±¹¼Ò); À¯Åë ä³Î(º´¿ø ¾à±¹ À¯Åë ä³Î, ¼Ò¸Å ¾à±¹ À¯Åë ä³Î, ¿Â¶óÀÎ ¾à±¹ À¯Åë ä³Î).

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Female Sexual Dysfunction Treatment Market to Reach US$853.8 Million by 2030

The global market for Female Sexual Dysfunction Treatment estimated at US$528.6 Million in the year 2024, is expected to reach US$853.8 Million by 2030, growing at a CAGR of 8.3% over the analysis period 2024-2030. Flibanserin, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$342.4 Million by the end of the analysis period. Growth in the Bremelanotide segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$144.0 Million While China is Forecast to Grow at 13.0% CAGR

The Female Sexual Dysfunction Treatment market in the U.S. is estimated at US$144.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$184.6 Million by the year 2030 trailing a CAGR of 13.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 8.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Global Female Sexual Dysfunction Treatment Market - Key Trends & Drivers Summarized

Why Is Female Sexual Dysfunction Finally Receiving Clinical and Commercial Attention?

After decades of limited recognition, female sexual dysfunction (FSD) is now being acknowledged as a significant and multifaceted health issue, spurring focused clinical attention and market development. Affecting an estimated 40-50% of women globally at some point in their lives, FSD encompasses a range of conditions including low libido (hypoactive sexual desire disorder), arousal disorders, orgasmic dysfunction, and pain-related conditions like dyspareunia. Historically underdiagnosed due to societal taboos, stigma, and lack of medical training, this condition is increasingly being seen as a legitimate component of women’s overall health and well-being. The shift is due in part to evolving cultural attitudes, a growing female voice in health advocacy, and increased demand for sexual wellness solutions beyond reproductive health. In response, healthcare providers and pharmaceutical companies are beginning to approach FSD with the same scientific rigor applied to male sexual dysfunction. This includes the development of specific diagnostic criteria, FDA-approved therapies like flibanserin and bremelanotide, and a growing body of clinical research dedicated to understanding hormonal, neurological, psychological, and relational factors underlying FSD.

How Are Pharmaceutical and Non-Pharmaceutical Innovations Changing the Treatment Landscape?

The treatment landscape for FSD is expanding beyond hormone-based solutions to include a wider spectrum of pharmaceutical and non-pharmaceutical options. Traditional therapies such as estrogen replacement or androgen therapy are now being complemented by centrally acting agents like flibanserin, which targets serotonin and dopamine pathways to enhance sexual desire. Bremelanotide, a melanocortin receptor agonist, represents another breakthrough, offering on-demand therapy for premenopausal women. Alongside these, researchers are exploring novel classes of drugs including oxytocin analogs and selective estrogen receptor modulators, with several in various stages of clinical trials. Non-pharmacological approaches are also gaining traction, particularly among women seeking holistic or non-invasive alternatives. These include cognitive-behavioral therapy, mindfulness-based interventions, pelvic floor physiotherapy, and the use of high-tech devices like vaginal lasers and neuromodulation tools. Telemedicine platforms and digital therapeutics are making treatment more accessible, discreet, and customizable, especially for women in underserved or conservative settings. The integration of sexual wellness into broader women’s health apps is further destigmatizing FSD and facilitating symptom tracking, behavior modification, and virtual counseling.

What Cultural, Psychological, and Demographic Shifts Are Driving Treatment Uptake?

Shifts in cultural narratives, psychological awareness, and demographic patterns are collectively driving a higher demand for FSD treatments. Women today are more empowered to prioritize their sexual well-being and communicate openly with healthcare providers, thanks to broader social acceptance and education surrounding female sexuality. Millennials and Gen Z, in particular, are helping redefine sexual health as a quality-of-life issue rather than a taboo topic, while postmenopausal women-often overlooked in the past-are demanding solutions that address age-related changes in libido and comfort. Additionally, rising awareness of mental health’s connection to sexual function has made psychological factors like anxiety, body image, and relationship dynamics part of the diagnostic and treatment process. In parallel, the popularity of wellness culture, body positivity, and sex-positive feminism has propelled a consumer-driven demand for products and services that support sexual fulfillment. As a result, women are increasingly turning to specialized clinics, online platforms, and retail wellness brands for both clinical treatments and lifestyle-enhancing supplements. These attitudinal shifts are creating a more receptive market environment and encouraging more robust discussions between patients and providers.

Which Industry Forces and Clinical Needs Are Accelerating Global Market Growth?

The growth in the Female Sexual Dysfunction Treatment market is driven by several factors rooted in medical advancements, shifting consumer preferences, and the evolution of healthcare delivery systems. Key among them is the increasing number of women seeking medical intervention for sexual wellness, supported by greater awareness, education, and accessibility to women-centric healthcare services. Pharmaceutical companies are actively investing in R&D for targeted therapies, with a growing pipeline of drugs addressing multiple FSD subtypes and hormonal profiles. The expansion of telehealth and direct-to-consumer platforms has drastically improved access to confidential consultations and prescription services, especially in markets where in-person discussions around sexual health remain taboo. Rising healthcare expenditure and insurance coverage in developed countries are also enabling more women to explore both traditional and emerging treatments. In addition, the aging global female population-especially in regions with high life expectancy-is creating sustained demand for postmenopausal sexual health solutions. Cross-sector collaborations between gynecologists, endocrinologists, mental health professionals, and sexual health specialists are enhancing multidisciplinary care models that better address the complex nature of FSD. The market is further energized by the wellness industry’s investment in sexual health, with nutraceuticals, lubricants, and tech-enabled therapy solutions contributing to a holistic ecosystem of FSD care.

SCOPE OF STUDY:

The report analyzes the Female Sexual Dysfunction Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug (Flibanserin, Bremelanotide, Ospemifene, Estrogen Therapy, Other Drugs); Disease (Dyspareunia Disease, Hypoactive Sexual Desire Disorder Disease, Other Diseases); Route of Administration (Oral, Parenteral, Topical); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â